A phase 2 trial in mixed phenotype acute leukemia shows that “big things” can happen regardless of where patients live or the rarity of their diseases.
Ashkan Emadi, MD, PhD
Advertisement
Articles by Ashkan Emadi, MD, PhD
A phase 2 trial will determine whether subcutaneous blinatumomab can offer benefit to a patient population with no other treatment options.
Advertisement
Latest Updated Articles
First-in-World Trial Explores Subcutaneous Blinatumomab in Rare LeukemiaFebruary 18th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
Anbenitamab Injection Combo Meets pCR End Point in HER2+ Breast Cancer
2
CAR-T Moves to the Front Line: Rethinking the Multiple Myeloma Sequence
3
Urine-Based Biopsy Shows 97.8% Sensitivity in Prostate Cancer Detection
4
ELCC 2026: Key Updates Across Non–Small Cell Lung Cancer Populations
5